Ionis Pharmaceuticals (NASDAQ:IONS) majority-owned affiliate Akcea Therapeutics (NASDAQ:AKCA) announces the
publication of long-term data from the NEURO-TTR study evaluating
Tegsedi (inotersen) in patients with hereditary transthyretin (hATTR)
amyloidosis with polyneuropathy. The results are in the latest edition
of the European Journal of Neurology.
The data showed that treatment with Tegsedi was
not associated with additional safety issues or signs of increased
toxicity for up to five years. Also, patients who started treatment
earlier than those who switched from placebo achieved greater long-term
disease stabilization.
The FDA approved antisense oligonucleotide for the indication in October 2018.
https://seekingalpha.com/news/3578226-akceas-tegsedi-shows-sustained-benefit-in-hattr-extension-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.